Table 4

The performance of remission criteria when patients with at least two visits in remission during the radiographic follow-up period are selected (patients did not have to be in remission at baseline, visits did not have to be consecutive)

Remission criteriaRemission and no progression (%)Not remission and no progression (%)SensitivitySpecificityLR+ (95% CI)Unadjusted OR (95% CI)
DAS28–CRP at ≥2 visits, n=13973570.310.821.8 (1.3 to 2.5)2.1 (1.4 to 3.2) p=0.001
SDAI at ≥2 visits, n=4486590.120.974.0 (1.7 to 9.4)4.5 (1.9 to 10.8) p=0.001
CDAI at ≥2 visits, n=4185590.110.973.7 (1.6 to 8.7)4.1 (1.7 to 9.8) p=0.002
ACR/EULAR at ≥2 visits, n=4183590.100.973.1 (1.4 to 6.9)3.5 (1.5 to 7.7) p=0.004
SJC 0 at ≥2 visits, n=10281560.260.912.8 (1.8 to 4.7)3.4 (2.0 to 5.8) p<0.001
  • Sensitivity, specificity, positive likelihood ratios and logistic regression models, all with absence of progression as the outcome (good radiographic outcome, change in TSS <1 unit/year).

  • ACR, American College of Rheumatology; CDAI, clinical disease activity index; DAS28–CRP, disease activity score based on 28 joint count and C-reactive protein; EULAR, European League Against Rheumatism; LR+, positive likelihood ratio; SDAI, simplified disease activity index; SJC, swollen joint count; TSS, van der Heijde modified Sharp score.